Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer

Yoshihama, Tomoko; Nomura, Hiroyuki; Iwasa, Naomi; Kataoka, Fumio; Hashimoto, S.; Nanki, Yoshiko; Hirano, Takuro; Makabe, Takeshi; Sakai, Kensuke; Yamagami, Wataru; Hirasawa, Akira; Aoki, Daisuke

doi:10.1093/jjco/hyx118

Cited by 9 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The safety profile reported here was similar to that observed in a single-center series of advanced OC cases, of whom 10% had grade 3 anemia, and 20% developed a grade 3 neutrophil count decrease [ 14 ]. In contrast, in Yoshihama et al [ 30 ], of the advanced OC cases treated with solvent-based paclitaxel, 8% had grade 4 hematologic toxicity, 56% had grade > 3 anemia, 24% required transfusion and/or granulocyte colony-stimulating factor, and 8% had grade > 3 non-hematologic toxicity. In a study by Kim et al [ 31 ], a grade > 3 neutrophil count decrease was detected in 22% of cases.…”

Section: Discussionmentioning

confidence: 94%

Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study

Wang

Zhu

et al. 2023

J Gynecol Oncol

View full text Add to dashboard Cite

Objective To evaluate the effectiveness and safety of nab-paclitaxel plus platinum as first-line chemotherapy for ovarian cancer (OC). Methods Patients administered platinum combined with nab-paclitaxel as first-line chemotherapy for epithelial OC, fallopian tube cancer, or primary peritoneal cancer from July 2018 to December 2021 were retrospectively evaluated. The primary outcome was progression-free survival (PFS). Adverse events (AEs) were examined. Subgroup analysis was performed. Results Seventy-two patients (median age, 54.5 years; range, 20.0–79.0 years) were evaluated, including 12 and 60 administered neoadjuvant therapy and primary surgery with subsequent chemotherapy, respectively. The median follow-up duration was 25.6 months, and the median PFS was 26.7 (95% confidence interval [CI]=24.0–29.3) months in the whole patient population. In the neoadjuvant subgroup, the median PFS was 26.7 (95% CI=22.9–30.5) months vs. 30.1 (95% CI=23.1–37.1) months in the primary surgery subgroup. Twenty-seven patients were administered nab-paclitaxel plus carboplatin and had a median PFS of 30.3 (95% CI=not available [NA]–NA) months. The commonest grade 3–4 AEs included anemia (15.3%), white blood cell decreased (11.1%), and neutrophil count decreased (20.8%). No drug-related hypersensitivity reactions occurred. Conclusion Nab-paclitaxel plus platinum as first-line treatment in OC was associated with a favorable prognosis and was tolerable in patients with OC.

show abstract

Section: Discussionmentioning

confidence: 94%

Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study

Wang

Zhu

et al. 2023

J Gynecol Oncol

View full text Add to dashboard Cite

show abstract

“…Despite the least favorable PFS results, the DD chemotherapy [ 1 1 7 _ T D $ D I F F ] alone group exhibited a more advantageous outcome than what was depicted in the Yoshihama et al neoadjuvant chemotherapy study (27.6 months vs. 17.7) for the treatment of advanced stage ovarian cancer [16]. Moreover, the results in the current study coincide with the 28 and 25.4 months [ 1 1 8 _ T D $ D I F F ] referenced in the Katsumata et al and Oskay-Ozcelik et al investigations [3,17].…”

Section: Commentsmentioning

confidence: 90%

A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma

Rettenmaier¹,

Micha

Bohart³

et al. 2020

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

“…Based on historical data, the proportion of patients who experience G3 or more treatmentrelated adverse events (TRAEs) in the neoadjuvant chemotherapy will be approximately 30%-50%, even without durvalumab and tremelimumab [8][9][10].…”

Section: Safety Run-in Phasementioning

confidence: 99%

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D

et al. 2019

View full text Add to dashboard Cite

BackgroundA single-arm phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in the treatment of advanced-stage ovarian cancer has begun in Korea. We hypothesized that adding durvalumab (anti-programmed death-ligand 1 antibody) and tremelimumab (anti-cytotoxic T-lymphocyte-associated protein 4 antibody) to chemotherapy in treating this cancer can increase progression-free survival (PFS) with minimal effects on safety.MethodsDuring treatment, serial biopsies will be performed on pre-treatment, at interval debulking surgery and progression to identify immune biomarkers and changes in the tumor microenvironment. Patients with histologically confirmed stage IIIC/IV epithelial ovarian cancer are offered durvalumab, tremelimumab plus chemotherapy for neoadjuvant chemotherapy and durvalumab plus chemotherapy for adjuvant chemotherapy. Twenty-four patients will be included from four Korean institutions within 1 year. The primary endpoint is a 12-month PFS rate.Trial RegistrationClinicalTrials.gov Identifier: NCT03899610

show abstract

Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer

Abstract: This study showed that ddTC therapy was considerably effective and tolerable as NAC. The complete surgery rate was high with IDS, and perioperative complications were acceptable.

Cited by 9 publications

References 21 publications

Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study

Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study

A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D

Contact Info

Product

Resources

About